<DOC>
	<DOCNO>NCT01421069</DOCNO>
	<brief_summary>This 8-year extension study pediatric subject diagnose one 3 subtypes Juvenile Idiopathic Arthritis ( JIA ) [ extend oligoarticular JIA , enthestitis relate arthritis ( ERA ) , psoriatic arthritis ( PsA ) ] complete approximately 96 week participation study 0881A1-3338 ( B1801014 ) . The study contain active treatment period , withdrawal/re-treatment period observational period ( non-treatment ) .</brief_summary>
	<brief_title>Extension Study Evaluating Etanercept 3 Subtypes Childhood Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Receipt least 1 dose investigational product ( etanercept ) participation approximately 96 week study 0881A13338 ( B1801014 ) Personally sign date informed consent document ( assent document , applicable ) indicate subject ( legally representative/guardian ) inform pertinent aspect study . Exclusion criterion subject plan continue investigational product : withdrawal investigational product study 0881A13338 reason ( safety nonsafety ) . History maliginancy squamous cell , basal cell carcinoma cervical carcinoma situ .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Use etanercept treat pediatric subject extend oligoarticular JIA</keyword>
	<keyword>enthestitis relate arthritis ( ERA )</keyword>
	<keyword>psoriatic arthritis ( PsA ) .</keyword>
</DOC>